MedTrace Logo

Onset and Duration of Mometasone by Oscillometry and Spirometry

NCT01635088 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2013-09-04

No results posted yet for this study

Summary

Inhaled corticosteroids (ICS) are appreciated for their long term anti-inflammatory effects in chronic asthma. However, they also have largely unappreciated early effects when initiated as a controller therapy in a steroid-naïve population. Impulse oscillometry might reveal such an early effect better than spirometry. The investigators sought to examine the onset of action and sustained effects over 4 weeks treatment of mometasone furoate as measured by Impulse Oscillometry System (IOS) versus spirometry.

Conditions

Interventions

DRUG

Mometasone furoate 220

dry powder inhaler QD for 28-43 days

DEVICE

KoKo Spirometry

DRUG

Mometasone furoate 440

dry powder inhaler QD for 28-43 days

DEVICE

Oscillometry

Sponsors & Collaborators

  • California Allergy and Asthma Medical Group, Inc.

    lead OTHER

Principal Investigators

  • Sheldon L Spector, MD · California Allergy and Asthma Medical Group, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01635088 on ClinicalTrials.gov